GRI Bio Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
GRI
- Investments
-
1
- Share Price
-
$0.71
- (As of Thursday Closing)
GRI Bio General Information
Description
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Contact Information
Website
www.gribio.comCorporate Office
- 2223 Avenida De La Playa
- Suite 208
- La Jolla, CA 92037
- United States
Corporate Office
- 2223 Avenida De La Playa
- Suite 208
- La Jolla, CA 92037
- United States
GRI Bio Timeline
GRI Bio Stock Performance
As of 16-Jan-2025, GRI Bio’s stock price is $0.71. Its current market cap is $6.3M with 8.93M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.71 | $0.73 | $0.30 - $65.00 | $6.3M | 8.93M | 3.83M | $77.53 |
GRI Bio Financials Summary
As of 30-Sep-2024, GRI Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (5,155) | (1,720) | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (8,285) | (10,951) | (2,561) | (963) |
| Net Income | (8,263) | (13,037) | (3,217) | (1,559) |
| Total Assets | 5,459 | 2,956 | 383 | 218 |
| Total Debt | 131 | 14 | 673 | 3,614 |
GRI Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GRI Bio Comparisons
Industry
Financing
Details
GRI Bio Competitors (1)
One of GRI Bio’s competitors is AllCells, a Private Equity-Backed company based in Alameda, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AllCells | Private Equity-Backed | Alameda, CA |
GRI Bio Patents
GRI Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3943066-A1 | Abuse deterrent formulations of amphetamine | Active | 06-Feb-2017 | ||
| EP-3576719-B8 | Abuse deterrent formulations of amphetamine | Active | 06-Feb-2017 | ||
| EP-3943066-B1 | Abuse deterrent formulations of amphetamine | Active | 06-Feb-2017 | ||
| EP-3576719-B1 | Abuse deterrent formulations of amphetamine | Active | 06-Feb-2017 | ||
| EP-3576719-A1 | Abuse deterrent formulations of amphetamine | Active | 06-Feb-2017 | A61K9/4866 |
GRI Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GRI Bio Acquisitions (1)
GRI Bio’s most recent deal was a Merger/Acquisition with Vallon Pharmaceuticals. The deal was made on 21-Apr-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vallon Pharmaceuticals | 21-Apr-2023 | Merger/Acquisition | Pharmaceuticals |
GRI Bio FAQs
-
When was GRI Bio founded?
GRI Bio was founded in 2009.
-
Where is GRI Bio headquartered?
GRI Bio is headquartered in La Jolla, CA.
-
What is the size of GRI Bio?
GRI Bio has 4 total employees.
-
What industry is GRI Bio in?
GRI Bio’s primary industry is Biotechnology.
-
Is GRI Bio a private or public company?
GRI Bio is a Public company.
-
What is GRI Bio’s stock symbol?
The ticker symbol for GRI Bio is GRI.
-
What is the current stock price of GRI Bio?
As of 16-Jan-2025 the stock price of GRI Bio is $0.71.
-
What is the current market cap of GRI Bio?
The current market capitalization of GRI Bio is $6.3M.
-
Who are GRI Bio’s competitors?
AllCells is a competitor of GRI Bio.
-
What is GRI Bio’s annual earnings per share (EPS)?
GRI Bio’s EPS for 12 months was $77.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
